Tim Crook

14.6k citations

129 papers · 12.3k · 1 hit paper · h-index 56

Impact in

Oncology top 0.5%
- Cancer-related Molecular Pathways
- Viral-associated cancers and disorders
Cancer Research top 1%

Papers in

Oncology 51
- Cancer-related Molecular Pathways 36
- Viral-associated cancers and disorders 6
Molecular Biology 44
- Epigenetics and DNA Methylation 28

Co-authors: Milena Gasco (18 shared papers)Karen H. Vousden (11 shared papers)Nelofer Syed (30 shared papers)JOHN A. TIDY (8 shared papers)Paul Smith (10 shared papers)Xin Lü (8 shared papers)Daniele Bergamaschi (6 shared papers)Martin J. Allday (9 shared papers)
Journals: British Journal of Cancer (14 papers)Oncogene (11 papers)The Lancet (5 papers)Blood (4 papers)Cell Death and Disease (4 papers)
Partner nations: United Kingdom Italy Greece

In The Last Decade

Tim Crook

126 papers receiving 11.9k citations

Tim Crook's Hit Papers

align trajectories log scale

DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis 2006 · 1.2k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2006 Cell

Peers

Countries citing papers authored by Tim Crook

Since Specialization

Citations

This map shows the geographic impact of Tim Crook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Crook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Crook more than expected).

Fields of papers citing papers by Tim Crook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Crook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Crook. The network helps show where Tim Crook may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim Crook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim Crook Line = papers co-authored together Tim Crook links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis Cell ·Diane Crighton, Simon Wilkinson, Jim O’Prey, Nelofer Syed, Paul Smith, Paul R. Harrison, Milena Gasco, Ornella Garrone Hit paper breakdown →	2006	1163
2	Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types Cell ·Tony G. Willis, Dalal M. Jadayel, Ming‐Qing Du, Huaizheng Peng, Amanda R. Perry, Munah Abdul-Rauf, Helen Philippa Price, Loraine Karran	1999	558
3	ASPP Proteins Specifically Stimulate the Apoptotic Function of p53 Molecular Cell ·Yardena Samuels, Daniel J O’Connor, Daniele Bergamaschi, Giuseppe Trigiante, Jung-Kuang Hsieh, Shan Zhong, Isabelle Campargue, Louie Naumovski	2001	542
4	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour Nature Genetics ·María C. Marín, Christine A. Jost, Louise A. Brooks, Meredith S. Irwin, Jenny O’Nions, JOHN A. TIDY, Nicholas David James, Jane McGregor	2000	441
5	Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation Cell ·Tim Crook, Karen H. Vousden, JOHN A. TIDY	1991	439
6	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer International Journal of Cancer ·Barbara Delage, Dean Anthony Fennell, Iain A. McNeish, Nicholas Robert Lemoine, Tim Crook, Peter Wojciech Szlosarek +1 other	2010	383
7	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell ·Daniele Bergamaschi, Milena Gasco, Louise Hiller, Nelofer Syed, Giuseppe Trigiante, Işık G. Yuluğ, Marco Carlo Merlano, Gianmauro Numico	2003	375
8	The p53 pathway in breast cancer Breast Cancer Research ·Milena Gasco, Shukri K. Shami, Tim Crook	2002	326
9	iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human Nature Genetics ·Daniele Bergamaschi, Yardena Samuels, Nigel J. O’Neil, Giuseppe Trigiante, Tim Crook, Jung-Kuang Hsieh, Daniel J O’Connor, Shan Zhong	2003	305
10	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response Nature ·Chiara Gorrini, Massimo Squatrito, Chiara Luise, Nelofer Syed, Daniele Perna, Landon Wark, Francesca Martinato, Domenico Sardella	2007	284
11	Yes-associated protein (YAP) functions as a tumor suppressor in breast Cell Death and Differentiation ·Ming Yuan, V Tomlinson, Romain Lara, Deborah L. Holliday, Claude Chelala, Takeshi Harada, Rathi Gangeswaran, Cleo L. Bishop	2008	280
12	Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours The Lancet ·Tim Crook, Casper David Wrede, JOHN A. TIDY, Karen H. Vousden, W. PETER MASON +1 other	1992	269
13	A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer Cancer Cell ·Javier E. Girardini, Marco Napoli, Silvano Piazza, Alessandra Rustighi, Carolina Marotta, Enrico Radaelli, Valeria Capaci, Lee B. Jordan	2011	248
14	iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 Nature Genetics ·Daniele Bergamaschi, Yardena Samuels, Marketa Zvelebil, Hilde Breyssens, Andrea Bisso, Giannino Del Sal, Nelofer Syed, Paul D. Smith	2006	218
15	Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo Oncogene ·Nelofer Syed, Milena Gasco, Daniele Bergamaschi, Giuseppe Trigiante, Marlene Attard, Louise Hiller, Paul J. Farrell, Paul Smith	2004	215
16	Continued expression of HPV‐16 E7 protein is required for maintenance of the transformed phenotype of cells co‐transformed by HPV‐16 plus EJ‐ras. The EMBO Journal ·Tim Crook, Jay P. Morgenstern, Lionel Crawford, Lawrence Banks	1989	205
17	ASPP1 and ASPP2: Common Activators of p53 Family Members Molecular and Cellular Biology ·Daniele Bergamaschi, Yardena Samuels, Boquan Jin, Sai Duraisingham, Tim Crook, Xin Lü	2004	196
18	Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer Cancer Cell ·Elizabeth J. Iorns, Nicholas C. Turner, Richard J. R. Elliott, Nelofer Syed, Ornella Garrone, Milena Gasco, Andrew N.J. Tutt, Tim Crook	2008	183
19	Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation Journal of Virology ·Rachel C. Davies, Ray Hicks, Tim Crook, Jessica P Morris, Karen H. Vousden	1993	177
20	High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene ·Tim Crook, John Malcolm Nicholls, Louise A. Brooks, Jenny O’Nions, Martin J. Allday	2000	168

About Tim Crook

Tim Crook is a scholar working on Oncology, Molecular Biology, Epidemiology, Genetics and Hematology, having authored 129 papers that have together received 12.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (36 papers), Epigenetics and DNA Methylation (28 papers), Cervical Cancer and HPV Research (18 papers), Multiple Myeloma Research and Treatments (8 papers), Viral-associated cancers and disorders (6 papers), Glioma Diagnosis and Treatment (6 papers), BRCA gene mutations in cancer (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Oncology (3.6k citations), Cancer Research (1.2k citations), Otorhinolaryngology (389 citations), Biochemistry (421 citations) and Biotechnology (460 citations). Tim Crook has collaborated with scholars based in United Kingdom, Italy and Greece. Frequent co-authors include Milena Gasco, Karen H. Vousden, Nelofer Syed, JOHN A. TIDY, Paul Smith, Xin Lü, Daniele Bergamaschi, Martin J. Allday, Ornella Garrone and Barry A. Gusterson. Their work appears in journals such as British Journal of Cancer, Oncogene, The Lancet, Blood and Cell Death and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tim Crook

Impact in

Papers in i

In The Last Decade

Tim Crook

Tim Crook's Hit Papers

Peers

Countries citing papers authored by Tim Crook

Fields of papers citing papers by Tim Crook

All Works

About Tim Crook

Explore authors with similar magnitude of impact

Papers in